CL2012003012A1 - Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion. - Google Patents

Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.

Info

Publication number: CL2012003012A1
Authority: CL; Chile
Prior art keywords: salt; hydromorphone; naloxone; extended; preparation
Prior art date: 2010-05-10

Application number

CL2012003012A

Other languages

English (en)

Inventor

Helen Kathleen Danagher

Hassan Mohammad

Malcolm Walden

Geoffrey Gerard Hayes

Jonathon Oliver Whitehouse

Thinnayam Naganathan Krishnamurthy

Rincon Ricardo Alberto Vargas

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-10

Filing date

2012-10-26

Publication date

2014-02-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-10-26 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2014-02-21 Publication of CL2012003012A1 publication Critical patent/CL2012003012A1/es

Links

150000003839 salts Chemical class 0.000 title 2
238000013265 extended release Methods 0.000 title 1
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 title 1
229960001410 hydromorphone Drugs 0.000 title 1
239000000463 material Substances 0.000 title 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title 1
229960004127 naloxone Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
230000002035 prolonged effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CL2012003012A 2010-05-10 2012-10-26 Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion. CL2012003012A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10162428		2010-05-10

Publications (1)

Publication Number	Publication Date
CL2012003012A1 true CL2012003012A1 (es)	2014-02-21

Family

ID=42983574

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003012A CL2012003012A1 (es)	2010-05-10	2012-10-26	Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.

Country Status (35)

Country	Link
US (1)	US9700508B2 (es)
EP (1)	EP2568967B2 (es)
JP (1)	JP5671609B2 (es)
KR (2)	KR20130030260A (es)
CN (2)	CN102946870A (es)
AP (1)	AP3441A (es)
AR (1)	AR083150A1 (es)
AU (1)	AU2011252039B2 (es)
BR (1)	BR112012028773A2 (es)
CA (1)	CA2739751C (es)
CH (1)	CH705273B1 (es)
CL (1)	CL2012003012A1 (es)
CO (1)	CO6640216A2 (es)
CR (1)	CR20120549A (es)
DE (1)	DE112011101605T5 (es)
DK (1)	DK178741B1 (es)
EA (1)	EA201291211A1 (es)
EC (1)	ECSP12012236A (es)
ES (1)	ES2408343B2 (es)
GB (1)	GB2492037A (es)
GT (1)	GT201200304A (es)
IL (1)	IL222772B (es)
MX (1)	MX347105B (es)
MY (1)	MY157673A (es)
NI (1)	NI201200157A (es)
NO (1)	NO20121414A1 (es)
NZ (2)	NZ700732A (es)
PE (1)	PE20130657A1 (es)
SE (1)	SE1251371A1 (es)
SG (1)	SG184523A1 (es)
TN (1)	TN2012000488A1 (es)
TW (2)	TWI483748B (es)
UA (1)	UA106278C2 (es)
WO (1)	WO2011141488A2 (es)
ZA (1)	ZA201207603B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103002881B (zh)	2010-05-10	2015-09-02	欧洲凯尔特公司	载有活性剂的颗粒与额外活性剂的组合
ES2642788T3 (es)	2010-05-10	2017-11-20	Euro-Celtique S.A.	Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
SE1251371A1 (sv)	2010-05-10	2012-12-27	Euro Celtique Sa	Farmaceutiska kompositioner innefattande hydromorfon och naloxon
CN104768552A (zh) *	2012-09-03	2015-07-08	第一三共株式会社	含有盐酸氢吗啡酮的口服持续释放药物组合物
CA2795324C (en) *	2012-11-09	2015-07-14	Purdue Pharma	Pharmaceutical compositions comprising hydromorphone and naloxone
US9517208B2 (en) *	2013-03-15	2016-12-13	Purdue Pharma L.P.	Abuse-deterrent dosage forms
GB201313915D0 (en) *	2013-08-02	2013-09-18	Johnson Matthey Plc	Process
EP3068397A1 (en)	2013-11-13	2016-09-21	Euro-Celtique S.A.	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) *	2014-03-28	2019-03-12	Purdue Pharma	Reducing drug liking in a subject
EP3229785A2 (de) *	2014-12-08	2017-10-18	Develco Pharma Schweiz AG	Naloxon-monopräparat und mehrschichttablette
KR20220132551A (ko) *	2020-02-14	2022-09-30	테이코쿠 팔마 유에스에이, 인코포레이티드	국소용 날록손 조성물 및 그의 사용 방법

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE49324B1 (en)	1979-12-19	1985-09-18	Euro Celtique Sa	Controlled release compositions
US4457933A (en) *	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
HU190619B (en)	1983-11-11	1986-09-29	Bezzegh,Denes,Hu	Process for producing tablets with controlled dissolution of active ingredients
EP0164669B1 (de)	1984-06-13	1991-01-23	Röhm Gmbh	Verfahren zum Überziehen von Arzneiformen
US4769372A (en) *	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
GB8626098D0 (en) †	1986-10-31	1986-12-03	Euro Celtique Sa	Controlled release hydromorphone composition
EP0352361A1 (en) †	1988-07-29	1990-01-31	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
FR2653337B1 (fr)	1989-10-23	1992-02-07	Dow Corning Sa	Element a liberation prolongee et procede pour le fabriquer.
US5662933A (en)	1993-09-09	1997-09-02	Edward Mendell Co., Inc.	Controlled release formulation (albuterol)
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
DE4443105C2 (de)	1994-12-03	1997-03-13	Hoechst Ag	Verfahren zur Herstellung Molsidomin-haltiger Tabletten
US6488961B1 (en)	1996-09-20	2002-12-03	Ethypharm, Inc.	Effervescent granules and methods for their preparation
DE19651551C2 (de) *	1996-12-11	2000-02-03	Klinge Co Chem Pharm Fab	Opioidantagonisthaltige galenische Formulierung
US6306438B1 (en)	1997-07-02	2001-10-23	Euro-Celtique, S.A.	Stabilized sustained release tramadol formulations
EP1041987B1 (en)	1997-12-22	2006-04-19	Euro-Celtique S.A.	Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
ECSP003314A (es)	2000-01-11	2000-03-22		Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
PL210845B1 (pl)	2000-02-08	2012-03-30	Euro Celtique Sa	Sposób wytwarzania doustnej postaci dawki
US6716449B2 (en)	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
US20040115133A1 (en)	2000-05-10	2004-06-17	Wermeling Daniel P.	Intranasal opioid compositions
GB0102342D0 (en)	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
JP4522652B2 (ja)	2001-05-11	2010-08-11	エンドーファーマシューティカルズ，インコーポレイティド	乱用防止制御放出オピオイド投薬形態
CN101439024A (zh) *	2001-05-11	2009-05-27	恩德制药公司	抗滥用阿片样物质剂型
JP2004534056A (ja)	2001-06-08	2004-11-11	エンドーファーマシューティカルズ，インコーポレイティド	アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
PL367427A1 (en) *	2001-08-06	2005-02-21	Euro-Celtique S.A.	Opioid agonist formulations with releasable and sequestered antagonist
WO2003013479A1 (en)	2001-08-06	2003-02-20	Euro-Celtique S.A.	Compositions and methods to prevent abuse of opioids
US7332182B2 (en)	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
BRPI0211899B8 (pt)	2001-08-23	2021-05-25	Akzo Nobel Nv	processos para a preparação de um derivado de 14- hidroxinormorfinona e para a produção de noroximorfona
DE10146275A1 (de)	2001-09-18	2003-04-24	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
DE10215131A1 (de) *	2002-04-05	2003-10-16	Euro Celtique Sa	Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
ES2608006T3 (es)	2002-04-05	2017-04-05	Euro-Celtique S.A.	Preparación farmacéutica que contiene oxicodona y naloxona
CA2489071A1 (en)	2002-07-04	2004-01-15	Janssen Pharmaceutica N.V.	Solid dispersions comprising two different polymer matrixes
BRPI0409133B8 (pt)	2003-04-08	2021-05-25	Progenics Pharm Inc	preparações farmacêuticas estavéis compreendendo metilnaltrexona
BRPI0409128A (pt)	2003-04-08	2006-03-28	Progenics Pharm Inc	uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
MXPA05010821A (es)	2003-04-08	2006-03-30	Progenics Pharm Inc	Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
PE20050146A1 (es)	2003-04-30	2005-03-26	Purdue Pharma Lp	Forma de dosificacion transdermica resistente a la manipulacion
US9114199B2 (en)	2003-07-31	2015-08-25	Boston Scientific Scimed, Inc.	Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US20050079221A1 (en)	2003-10-10	2005-04-14	Groenewoud Pieter Jurjen	Ibuprofen narcotic composition and method for making same
US20050232987A1 (en)	2004-03-12	2005-10-20	Viswanathan Srinivasan	Dosage form containing a morphine derivative and another drug
US20050165038A1 (en)	2004-01-22	2005-07-28	Maxwell Gordon	Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
KR20070108956A (ko)	2004-02-06	2007-11-13	유로-셀띠끄 소시에떼 아노님	3-ｏ-보호된 모르피논 및 3-ｏ-보호된 모르피논 디엔올카르복실레이트 제조방법
TWI350762B (en)	2004-02-12	2011-10-21	Euro Celtique Sa	Particulates
US9016221B2 (en)	2004-02-17	2015-04-28	University Of Florida Research Foundation, Inc.	Surface topographies for non-toxic bioadhesion control
TW201509943A (zh)	2004-03-30	2015-03-16	Euro Celtique Sa	含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US7700626B2 (en)	2004-06-04	2010-04-20	Adolor Corporation	Compositions containing opioid antagonists
EP1604667A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en)	2004-08-31	2009-12-23	Euro Celtique Sa	Multiparticulates
WO2006038226A2 (en)	2004-10-08	2006-04-13	Rubicon Research Pvt. Ltd.	Process for making a highly compressible controlled delivery compositions of metformin
GB0423103D0 (en)	2004-10-19	2004-11-17	Boots Healthcare Int Ltd	Therapeutic agents
US20060205753A1 (en)	2005-01-20	2006-09-14	Israel Robert J	Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
JP5704789B2 (ja)	2005-01-28	2015-04-22	ユーロ−セルティークエス．エイ．	耐アルコール性剤形
EP1695700A1 (en)	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone
NL1028460C2 (nl) *	2005-03-04	2006-09-06	Sara Lee De Nv	Inrichting voor het bereiden en afgeven van al dan niet althans gedeeltelijk opgeschuimde dranken.
JP4741865B2 (ja)	2005-03-24	2011-08-10	共和薬品工業株式会社	ペルゴリド錠剤の製造方法
US20070026025A1 (en)	2005-04-12	2007-02-01	Aquegel Cosmetics, Llc	Topical ointment and method for making and using same
TWI366460B (en)	2005-06-16	2012-06-21	Euro Celtique Sa	Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070059360A1 (en)	2005-07-29	2007-03-15	Ashish Jaiswal	Water-dispersible anti-retroviral pharmaceutical compositions
US20070048364A1 (en)	2005-08-04	2007-03-01	Yingxu Peng	Free flowing granules containing carbomer
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2631498A1 (en)	2005-12-14	2007-06-21	F. Hoffmann-La Roche Ag	Hcv prodrug formulation
US20070141147A1 (en)	2005-12-21	2007-06-21	Auriga Laboratories, Inc.	Sequential release pharmaceutical formulations
EP1813276A1 (en)	2006-01-27	2007-08-01	Euro-Celtique S.A.	Tamper resistant dosage forms
US7799790B2 (en)	2006-07-20	2010-09-21	Helm Ag	Amorphous aripiprazole and process for the preparation thereof
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de)	2006-10-26	2008-04-30	Evonik Röhm Gmbh	Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
GB2447898B (en)	2007-03-24	2011-08-17	Reckitt Benckiser Healthcare	A tablet having improved stability with at least two actives
PT2379066E (pt)	2008-09-16	2014-07-04	Imuneks Farma Ilaç Sanayi Ve Ticaret A S	Uso de antagonistas opioides para a preparação de um medicamento no tratamento das doenças degenerativas da retina
JP5539991B2 (ja)	2008-09-18	2014-07-02	パーデュー、ファーマ、リミテッド、パートナーシップ	ポリ（ε−カプロラクトン）を含む医薬剤形
BRPI0823128B8 (pt)	2008-09-24	2022-07-05	Evonik Roehm Gmbh	composição farmacêutica de liberação controlada dependente do ph para não opioides com resistência contra a influência de etanol, e processo para sua preparação
JP5453433B2 (ja)	2008-09-24	2014-03-26	エボニックレームゲゼルシャフトミットベシュレンクテルハフツング	エタノールの影響に対する耐性を有するｐＨ依存の制御放出の医薬オピオイド組成物
CN102281876A (zh)	2008-10-30	2011-12-14	格吕伦塔尔有限公司	新型有效的他喷他多剂型
US20100143486A1 (en)	2008-12-10	2010-06-10	Nipun Davar	Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
BRPI0923836A2 (pt)	2008-12-31	2015-07-21	Upsher Smith Lab Inc	Composições farmacêuticas orais contendo opióide e métodos
WO2010081034A2 (en)	2009-01-09	2010-07-15	President And Fellows Of Harvard College	Fluorine containing compounds and methods of use thereof
US20100183687A1 (en)	2009-01-22	2010-07-22	Cox D Phillip	Process for preparing particles of opioids and compositions produced thereby
NZ594208A (en)	2009-02-06	2012-10-26	Egalet Ltd	Pharmaceutical compositions resistant to abuse
US8431701B2 (en)	2009-02-17	2013-04-30	Mallinckrodt Llc	Process for the reductive alkylation of normorphinans
CN102325776A (zh)	2009-02-23	2012-01-18	马林克罗特公司	(+)-吗啡喃*季盐及其制备方法
CN102325777B (zh)	2009-02-23	2015-08-12	马林克罗特公司	(+)-吗啡喃*n-氧化物及其制备方法
US20100227876A1 (en)	2009-03-06	2010-09-09	Rechfensen Llp	Methods of Reducing Side Effects of Analgesics
RU2522212C2 (ru)	2009-03-10	2014-07-10	Еуро-Селтик С.А.	Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
EP2408436B1 (en)	2009-03-18	2017-02-22	Evonik Röhm GmbH	Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
EP2408437A1 (en)	2009-03-18	2012-01-25	Evonik Röhm GmbH	Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
AU2010231126A1 (en)	2009-04-02	2011-10-13	Shire Llc	Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
EP2419398A4 (en)	2009-04-14	2012-11-28	Infiniton Ab	PRO-BET WITH BETA-KETO-CARBOXYLIC ACID, BETA-KETO-CARBOXYLIC ACID SALT OR BETA-KETO-CARBOXYLIC ACID ESTERS FOR ACTIVE INHIBITION
WO2010123999A2 (en)	2009-04-21	2010-10-28	Auspex Pharmaceuticals, Inc.	1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
EP2421508B1 (en)	2009-04-24	2016-12-14	Omya International AG	Particulate material for controlled release of active ingredients
WO2010141505A1 (en)	2009-06-01	2010-12-09	Protect Pharmaceutical Corporation	Abuse-resistant delivery systems
GB0909680D0 (en)	2009-06-05	2009-07-22	Euro Celtique Sa	Dosage form
CA2764915C (en)	2009-06-11	2017-07-11	Mallinckrodt Llc	Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer
FR2946533A1 (fr)	2009-06-12	2010-12-17	Ethypharm Sa	Reduction des fluctuations plasmatiques d'opioides.
US8829020B2 (en)	2009-07-16	2014-09-09	Mallinckrodt Llc	Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
MX2012000317A (es)	2009-07-22	2012-02-08	Gruenenthal Gmbh	Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
JP2012533585A (ja)	2009-07-22	2012-12-27	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	酸化感受性オピオイドのための不正使用防止剤形
GB0914338D0 (en)	2009-08-17	2009-09-30	Johnson Matthey Plc	Improved process
EP2475429B1 (en)	2009-09-08	2015-07-29	Signature Therapeutics, Inc.	Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
WO2011041470A2 (en)	2009-09-30	2011-04-07	Mallinckrodt Inc.	Sustained-release opiate and opiate derivative compositions
EP2488029B1 (en)	2009-09-30	2016-03-23	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse
ES2642788T3 (es)	2010-05-10	2017-11-20	Euro-Celtique S.A.	Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
CN103002881B (zh)	2010-05-10	2015-09-02	欧洲凯尔特公司	载有活性剂的颗粒与额外活性剂的组合
SE1251371A1 (sv)	2010-05-10	2012-12-27	Euro Celtique Sa	Farmaceutiska kompositioner innefattande hydromorfon och naloxon
GB201020895D0 (en)	2010-12-09	2011-01-26	Euro Celtique Sa	Dosage form

2011
- 2011-05-10 SE SE1251371A patent/SE1251371A1/sv not_active Application Discontinuation
- 2011-05-10 MX MX2012013119A patent/MX347105B/es active IP Right Grant
- 2011-05-10 ES ES201290081A patent/ES2408343B2/es not_active Expired - Fee Related
- 2011-05-10 PE PE2012002146A patent/PE20130657A1/es not_active Application Discontinuation
- 2011-05-10 EA EA201291211A patent/EA201291211A1/ru unknown
- 2011-05-10 AP AP2012006606A patent/AP3441A/xx active
- 2011-05-10 GB GB1219275.3A patent/GB2492037A/en not_active Withdrawn
- 2011-05-10 TW TW100116427A patent/TWI483748B/zh not_active IP Right Cessation
- 2011-05-10 BR BR112012028773A patent/BR112012028773A2/pt not_active Application Discontinuation
- 2011-05-10 US US13/697,197 patent/US9700508B2/en active Active
- 2011-05-10 CN CN2011800231922A patent/CN102946870A/zh active Pending
- 2011-05-10 CA CA2739751A patent/CA2739751C/en not_active Expired - Fee Related
- 2011-05-10 AU AU2011252039A patent/AU2011252039B2/en not_active Ceased
- 2011-05-10 WO PCT/EP2011/057566 patent/WO2011141488A2/en active Application Filing
- 2011-05-10 AR ARP110101621A patent/AR083150A1/es unknown
- 2011-05-10 CH CH02357/12A patent/CH705273B1/de not_active IP Right Cessation
- 2011-05-10 EP EP11718747.6A patent/EP2568967B2/en active Active
- 2011-05-10 TW TW103137424A patent/TWI590835B/zh not_active IP Right Cessation
- 2011-05-10 KR KR1020127029438A patent/KR20130030260A/ko not_active Application Discontinuation
- 2011-05-10 MY MYPI2012004553A patent/MY157673A/en unknown
- 2011-05-10 NZ NZ700732A patent/NZ700732A/en not_active IP Right Cessation
- 2011-05-10 KR KR1020157004528A patent/KR101858797B1/ko active IP Right Grant
- 2011-05-10 NZ NZ603497A patent/NZ603497A/en not_active IP Right Cessation
- 2011-05-10 JP JP2013509554A patent/JP5671609B2/ja not_active Expired - Fee Related
- 2011-05-10 CN CN201610284534.0A patent/CN105832687A/zh active Pending
- 2011-05-10 DE DE112011101605T patent/DE112011101605T5/de not_active Withdrawn
- 2011-05-10 SG SG2012075040A patent/SG184523A1/en unknown
- 2011-10-05 UA UAA201212796A patent/UA106278C2/uk unknown
2012
- 2012-10-08 EC ECSP12012236 patent/ECSP12012236A/es unknown
- 2012-10-09 TN TNP2012000488A patent/TN2012000488A1/en unknown
- 2012-10-10 ZA ZA2012/07603A patent/ZA201207603B/en unknown
- 2012-10-22 NI NI201200157A patent/NI201200157A/es unknown
- 2012-10-26 CL CL2012003012A patent/CL2012003012A1/es unknown
- 2012-10-29 CR CR20120549A patent/CR20120549A/es unknown
- 2012-10-30 IL IL222772A patent/IL222772B/en not_active IP Right Cessation
- 2012-11-05 DK DKPA201270677A patent/DK178741B1/da not_active IP Right Cessation
- 2012-11-08 CO CO12201488A patent/CO6640216A2/es unknown
- 2012-11-09 GT GT201200304A patent/GT201200304A/es unknown
- 2012-11-26 NO NO20121414A patent/NO20121414A1/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP5671609B2 (ja)	2015-02-18
AP2012006606A0 (en)	2012-12-31
NZ700732A (en)	2015-08-28
CN105832687A (zh)	2016-08-10
US9700508B2 (en)	2017-07-11
GB2492037A (en)	2012-12-19
AU2011252039B2 (en)	2014-06-12
SG184523A1 (en)	2012-11-29
DK178741B1 (da)	2016-12-19
KR20150028367A (ko)	2015-03-13
AP3441A (en)	2015-10-31
CA2739751A1 (en)	2011-11-10
AU2011252039A1 (en)	2012-11-08
CH705273B1 (de)	2016-06-15
US20130178492A1 (en)	2013-07-11
TW201503913A (zh)	2015-02-01
WO2011141488A3 (en)	2012-04-05
CR20120549A (es)	2013-03-08
ES2408343B2 (es)	2014-07-17
IL222772A0 (en)	2012-12-31
CA2739751C (en)	2014-08-12
PE20130657A1 (es)	2013-06-15
AR083150A1 (es)	2013-02-06
KR20130030260A (ko)	2013-03-26
ES2408343A2 (es)	2013-06-20
GT201200304A (es)	2014-06-09
CN102946870A (zh)	2013-02-27
EP2568967B2 (en)	2022-07-27
JP2013526508A (ja)	2013-06-24
MX2012013119A (es)	2013-02-11
GB201219275D0 (en)	2012-12-12
WO2011141488A2 (en)	2011-11-17
ECSP12012236A (es)	2013-02-28
IL222772B (en)	2018-11-29
TWI590835B (zh)	2017-07-11
KR101858797B1 (ko)	2018-05-16
MX347105B (es)	2017-04-12
DK201270677A (en)	2012-11-05
MY157673A (en)	2016-07-15
NI201200157A (es)	2013-02-05
SE1251371A1 (sv)	2012-12-27
TW201206501A (en)	2012-02-16
EA201291211A1 (ru)	2013-05-30
CO6640216A2 (es)	2013-03-22
NO20121414A1 (no)	2013-02-11
EP2568967B1 (en)	2018-10-24
EP2568967A2 (en)	2013-03-20
TWI483748B (zh)	2015-05-11
ZA201207603B (en)	2014-12-23
BR112012028773A2 (pt)	2016-07-19
DE112011101605T5 (de)	2013-04-25
TN2012000488A1 (en)	2014-04-01
UA106278C2 (uk)	2014-08-11
NZ603497A (en)	2015-02-27
ES2408343R1 (es)	2013-08-28

Publication	Publication Date	Title
CL2012003012A1 (es)	2014-02-21	Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
IL241361A (en)	2017-01-31	Use of a medicinal product containing a main species of her2-acidic variants for the preparation of a pharmaceutical product
JP2007527914A5 (es)	2008-04-10
EP2120878A4 (en)	2013-05-08	DOSAGE FORM WITH TWO OR MORE PHARMACEUTICAL ACTIVITIES IN DIFFERENT PHYSICAL FORMS
IL223783B (en)	2018-06-28	Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
PT2344198T (pt)	2020-12-04	Preparações farmacêuticas à base de lípidos para aplicação tópica
ATE517619T1 (de)	2011-08-15	Stabilisierte pharmazeutische zusammensetzung mit fesoterodin
BRPI0818193A2 (pt)	2017-12-12	composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
CL2011001621A1 (es)	2012-03-30	Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
CL2013000444A1 (es)	2013-08-23	Composicion farmaceutica oral de liberacion prolongada que comprende un material de liberacion prolongada, y oxicodona y naloxona, cuya composicion farmaceutica almacenada en condiciones de estres tiene menos de un 4% de sustancias relacionadas con oxicodona y naloxona; y uso de un aglutinante para fabricar dicha composicion.
CL2007002921A1 (es)	2008-05-30	Forma solida de dosificacion farmaceutica de administracion oral, que comprende una forma cristalina o amorfa de un compuesto microincluido en un polimero ionico insoluble en agua en proporcion 5:1 a 1:5; y metodo de preparacion.
CL2014000844A1 (es)	2014-09-12	Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada.
BRPI0913822A2 (pt)	2015-10-20	forma farmacêutica oral e uso da forma farmacêutica
IL204658A (en)	2015-10-29	Pharmaceutical preparation for topical use in the form of an opaque gel-gel containing diclofenac diethylammonium salt
FR2934156B1 (fr)	2010-09-24	Medicament appetissant a administration orale sous forme solide
BRPI1013988A2 (pt)	2016-04-05	composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
EP1862183A4 (en)	2009-12-30	PHARMACEUTICAL COMPOSITION WITH HEAVY WATER-SOLUBLE MEDICAMENT
CO6801754A2 (es)	2013-11-29	Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
ATE505203T1 (de)	2011-04-15	Pharmazeutische kombination aus aliskiren und valsartan
CL2008000610A1 (es)	2008-09-05	Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
EP2261221A4 (en)	2011-08-10	EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS
CL2013001564A1 (es)	2014-05-02	Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
IL210204A (en)	2015-03-31	Ligand, a method for its preparation, an antibody and a pharmaceutical composition containing it and their use in the preparation of a drug for the treatment of MSRV-related disease
ECSP10010576A (es)	2010-12-30	Formulaciones orales e inyectables de compuestos de tetraciclina